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Abstract
Background: Interleukin-22 (IL-22), recently identified as a crucial parameter of pathology in experimental liver
damage, may determine survival in clinical end-stage liver disease. Systematic analysis of serum IL-22 in relation to
morbidity and mortality of patients with advanced liver cirrhosis has not been performed so far.
Methods: This is a prospective cohort study including 120 liver cirrhosis patients and 40 healthy donors to analyze
systemic levels of IL-22 in relation to survival and hepatic complications.
Results: A total of 71% of patients displayed liver cirrhosis-related complications at study inclusion. A total of 23%
of the patients died during a mean follow-up of 196 ± 165 days. Systemic IL-22 was detectable in 74% of patients
but only in 10% of healthy donors (P < 0.001). Elevated levels of IL-22 were associated with ascites (P = 0.006),
hepatorenal syndrome (P < 0.0001), and spontaneous bacterial peritonitis (P = 0.001). Patients with elevated IL-22
(>18 pg/ml, n = 57) showed significantly reduced survival compared to patients with regular (≤18 pg/ml) levels of
IL-22 (321 days versus 526 days, P = 0.003). Other factors associated with reduced overall survival were high CRP
(≥2.9 mg/dl, P = 0.005, hazard ratio (HR) 0.314, confidence interval (CI) (0.141 to 0.702)), elevated serum creatinine
(P = 0.05, HR 0.453, CI (0.203 to 1.012)), presence of liver-related complications (P = 0.028, HR 0.258, CI (0.077 to
0.862)), model of end stage liver disease (MELD) score ≥20 (P = 0.017, HR 0.364, CI (0.159 to 0.835)) and age (P =
0.011, HR 0.955, CI (0.922 to 0.989)). Adjusted multivariate Cox proportional-hazards analysis identified elevated
systemic IL-22 levels as independent predictors of reduced survival (P = 0.007, HR 0.218, CI (0.072 to 0.662)).
Conclusions: In patients with liver cirrhosis, elevated systemic IL-22 levels are predictive for reduced survival
independently from age, liver-related complications, CRP, creatinine and the MELD score. Thus, processes that lead
to a rise in systemic interleukin-22 may be relevant for prognosis of advanced liver cirrhosis.
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Background
Liver cirrhosis, virally-, drug- or alcohol-induced, is a
major health problem associated with significant morbidity
and mortality worldwide [1]. Identification of processes
that lead to deterioration of liver cirrhosis and develop-
ment of complications is regarded as key to successful
implementation of novel treatment regimes aiming at
hard-to-treat patients suffering from hepatitis of diverse
etiologies.
Interleukin (IL)-22 is among newly identified para-
meters of hepatocyte biology that recently became the
major focus of basic and translational research on liver
injury and inflammation [2]. This member of the IL-10
cytokine family is primarily produced by activated CD4
+
or CD8
+ T cells, gδ-T cells, macrophages/dendritic cells
and a diverse array of natural killer (NK)-like cells
recently coined innate lymphoid cells [3-5]. Enhanced
IL-22 expression is associated with diseases triggered by
or accompanied with immunoactivation, among others:
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toid arthritis [8] and abdominal sepsis [9]. IL-22 is bio-
chemically and functionally akin to IL-6 and able to
efficiently initiate the hepatic acute phase response
[10,11]. However, in contrast to IL-6, IL-22 almost exclu-
sively acts on non-leukocytic cells. As a result, cells of
epithelial origin, including hepatocytes, but not leuko-
cytes, are major targets of IL-22 [3-5]. Pathophysiological
functions of IL-22 as detected in rodent disease models
are strictly context specific. In fact, this cytokine appears
to be pathogenic in models of diseases associated with
autoimmunity and tissue hyperplasia, such as experimen-
tal psoriasis [12] and arthritis [13]. In contrast, IL-22 has
protective functions in models of microbe/infection-
driven inflammation at host/environment interfaces
[14-16], likely by up-regulating anti-microbial peptides
[3-5,14,15], inducible nitric oxide (NO) synthase [17,18]
and mucus production [16]. The tissue protective proper-
ties of IL-22 also extend to experimental ventilator-
i n d u c e dl u n gi n j u r y[ 1 9 ]a n d ,i np a r t i c u l a r ,t os p e c i f i c
models of hepatic diseases [5].
As already alluded to, the liver is regarded as a prime
target of IL-22 biological activity. Likely by promoting
hepatocyte survival, several studies indicate a protective
role for IL-22 in experimental hepatitis and liver injury
[20-22], a property that may on the other hand promote
progression to hepatocellular carcinoma [23]. However,
the role of IL-22 in liver disease is not unequivocal.
A recent report indicates that IL-22 may also amplify
liver injury in experimental hepatitis B virus infection
[24]. Notably, the course of hepatic disease in this con-
text depends on robust leukocyte infiltration, which is at
least in part dependent on IL-22 [24]. The potential of
IL-22 as a parameter of liver diseases is further high-
lighted by detection of its increased expression in
patients’ liver biopsy specimens [23,25,26]. Enhanced
levels of systemic IL-22 have recently been observed in
patients with chronic hepatitis [23] and acute hepatitis B
infection [24].
Liver cirrhosis, the end-stage of various liver diseases,
has a poor prognosis, which is determined by deteriora-
tion of hepatic functional capacity and consecutive devel-
opment of hepatic complications. In the cirrhotic liver,
IL-22 may be secreted to protect residual healthy liver
tissue. Assuming that IL-22 possesses hepatoprotective
properties in end-stage liver disease, IL-22 may be a rele-
vant factor for progression of liver cirrhosis. The prog-
nostic relevance of elevated IL-22 levels in patients with
end-stage liver disease has not been characterized so far.
Here we comprehensively analyzed systemic IL-22 con-
centrations in a cohort of 120 patients suffering from
severe liver cirrhosis and thoroughly related those data to
the survival of liver disease.
Methods
Study population and selection of patients
This prospective study investigated complications and
mortality in consecutive patients who were treated due to
advanced liver cirrhosis at the liver center of the Univer-
sity Hospital Frankfurt, Germany. The study protocol was
approved by the local ethics committee of the University
Hospital Frankfurt, Germany (reference number 84/09).
All patients gave written informed consent before inclu-
sion into the study. The study was performed in accor-
dance with the Declaration of Helsinki.
Inclusion criteria were age ≥18 years and the presence
of liver cirrhosis. Liver cirrhosis was either proven histo-
pathologically or by explicit morphological criteria of
liver cirrhosis with ultrasound, computer tomography or
magnetic resonance imaging. Exclusion criteria were
patients with organ transplantation and patients with
early to terminal stages of hepatocellular carcinoma.
Patients with diagnosis of hepatocellular carcinoma after
study inclusion were not excluded later on. The control
group consisted of healthy volunteers (n = 40, 32.4 years
± 8.4 years).
Evaluation of complications
The following forms of liver-related complications were
investigated during hospital admission: ascites, sponta-
neous bacterial peritonitis, hepatorenal syndrome, eso-
phageal variceal bleeding and hepatic encephalopathy.
The presence of ascites was confirmed by ultrasonogra-
phy. Paracentesis was performed if appropriate amounts
of ascites were detectable. Duplex sonography of the liver
veins as well as of the portal vein was performed each
time ascites was present. When Budd Chiari syndrome,
portal vein thrombosis or a malignant ascites was diag-
nosed at first admission, the patients were excluded. The
diagnosis of spontaneous bacterial peritonitis was based
on a neutrophil count >250 mm³ in ascites fluid and/or a
positive ascitic fluid culture. Hepatorenal syndrome was
diagnosed according to the EASL clinical practice guide-
line [1]. Type 1 hepatorenal syndrome was diagnosed
when the serum creatinine level was increased by more
than 100% above baseline to a final level >2.5 mg/dl dur-
ing the first hospitalization. Esophageal variceal bleeding
was diagnosed by endoscopy. Hepatic encephalopathy
was diagnosed according to clinical criteria, including
impairment of autonomy, consciousness, intellectual
function and behavior.
Study endpoints
The primary endpoint of this study was mortality in
patients with advanced liver cirrhosis. Furthermore, the
association between liver-related complications, such as
ascites, hepatorenal syndrome, spontaneous bacterial
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analyzed. In addition, the relation between IL-22 serum
levels and laboratory parameters as well as the model of
end stage liver disease (MELD) score was assessed.
Collection of blood samples
All samples for IL-22 baseline quantification were col-
lected at study inclusion. In hospitalized patients periph-
eral blood was collected within the first week of hospital
admission. Furthermore, blood was collected in consecu-
tive patients with liver cirrhosis coming to the outpatient
clinic. In addition, blood was collected during the follow-
up period. For follow-up analyses, blood was collected at
subsequent hospitalizations after study entry. Follow-up
serum samples were taken a minimum of 30 days apart
from the initial blood collection. Blood samples were sub-
sequently used for clinical chemistry and IL-22 quantifica-
tion. Serum tubes were centrifuged at 1,500 × g for
10 minutes at 4°C, followed by an additional centrifugation
step at 2,000 × g at 4°C to completely remove any remain-
ing cells. The serum samples were aliquoted and stored at
-80°C until further use.
Clinical chemistry
Hematology and biochemistry analyses were performed
at the local laboratory of the Frankfurt University
Hospital.
Quantification of IL-22 serum levels
Serum IL-22 levels were quantified by using the IL-22
Quantikine enzyme linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions.
T h i sa s s a yd e t e c t sam i n i m u mo f2 . 7p g / m lo fI L - 2 2
(R&D Systems, Inc., Minneapolis, MN, USA). All sam-
ples showing a value below this detection limit were set
to 2.6 pg/ml. Readers of the IL-22 ELISA were unaware
of the patients’ clinical characteristics.
IL-22 immunohistochemistry
Liver biopsies were performed using a 14-gauge modified
Menghini needle under ultrasound guidance and local
anesthesia. Liver biopsy specimens were fixed in formalin
and embedded in paraffin for routine staining with hema-
toxylin and eosin. For immunohistochemical staining,
10 μm paraffin sections were deparaffinized through
xylene and graded ethanol. For antigen retrieval, paraffin
sections were boiled in citrate buffer (10 mM, pH 6.0) for
30 minutes. Endogenous peroxidases were blocked by
incubation in a solution containing 3% H2O2 in methanol
for 10 minutes. IL-22 was detected by incubating the tis-
sue sections with a monoclonal anti-human anti-IL-22
antibody (clone ab50140, Abcam, Cambridge, UK)
for 1 h (dilution of 1:75) in humidified atmosphere.
Thereafter, the tissue slices were incubated with
horseradish peroxidase-labeled polymer conjugated goat
anti-mouse antibody (EnVision™,D a k o ,H a m b u r g ,
Germany) for 30 minutes. Diaminobenzidin was used as
chromogen.
Statistical analyses
The follow-up period started at study inclusion and
ended at the patient’s time of death, liver transplantation
or last contact. Death was recorded as an event. All
patients were seen every 4 to 12 weeks at the liver cen-
ter of the J.W. Goethe University Hospital. At the end
of the study, the patient’s physician was contacted. In
patients who were lost to follow-up before the end of
the study, the time in the study ranged from study
inclusion to last contact. Statistical analyses were per-
formed with SPSS (Version 17.0, IBM, New York, NY,
USA) and BiAS (Epsilon Verlag, Hochheim Darmstadt,
Germany). Overall survival rates were assessed for all
patients with the Kaplan-Meier method and compared
with the log-rank test. Correlations between two vari-
ables were assessed by the non-parametric Spearman
test.
The MELD score was calculated according to the stan-
dard formula as follows: 11.2 × ln (INR) + 9.57 × ln
(creatinine, in milligrams per deciliter) + 3.78 × ln (biliru-
bin, in milligrams per deciliter) + 6.43 with a lower limit
of 1 for all variables and with creatinine capped at 4.
A multivariate Cox proportional-hazards analysis using
forward stepwise variable selection was conducted to
describe the relationship between the systemic IL-22
serum level, the MELD score, CRP, age, creatinine, pre-
sence of liver-related complications and overall survival.
Furthermore, an area under the observed receiver operat-
ing curve (AUC) analysis was performed to compare the
performance of elevated IL-22 and the MELD score for
the prediction of survival.
Categorical variables were analyzed using the Fisher
test. Differences between paired and unpaired samples
were investigated with the non-parametric Wilcoxon
paired sample test, the Mann-Whitney U-test or the
Kruskal Wallis test. All tests were two-sided and a
P-value of < 0.05 was considered statistically significant.
Results
Patient characteristics
Between 2009 and 2011, 159 patients with liver cirrhosis
were screened. A total of 120 patients fulfilled the inclu-
sion criteria and were prospectively enrolled into the
present study (Figure 1). The patient characteristics are
shown in Table 1. The majority of patients was male.
The major causes of liver cirrhosis were alcoholic liver
damage, chronic viral hepatitis B or C, respectively. The
majority of patients presented with liver cirrhosis related
complications at inclusion into the study. The most
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patients with ascites, 19.1% had spontaneous bacterial
peritonitis and 32.4% hepatorenal syndrome. Criteria for
hepatorenal syndrome type 1 and 2 were fulfilled in 12
and 14 patients, respectively.
The patients were followed for a mean and maximum
duration of 195.7 ± 165.1 days and 651 days, respec-
tively. Twenty-eight patients (23.3%) died during the fol-
low-up period. All cases of death were considered as
related to deterioration of liver cirrhosis and complica-
tions. In two patients, hepatocellular carcinoma was
diagnosed after inclusion into the study. Twelve patients
(10%) received liver transplantation during the observa-
tion period.
IL-22 serum levels are increased in patients with liver
cirrhosis
To investigate whether liver cirrhosis is associated with
increased serum IL-22, the cytokine was determined in
sera of healthy donors and liver cirrhosis patients,
respectively. IL-22 was detectable (>2.6 pg/ml) in 89 of
120 patients with liver cirrhosis, but only in 4 of 40
healthy controls (74.1% vs. 10.0%, P < 0.001) (Figure 2).
The corresponding mean levels of serum IL-22 as detect-
able by ELISA were 10-fold higher in patients with liver
cirrhosis than in healthy donors (44.1 ± 68.4 and 4.6 ±
6.8 pg/ml, Figure 2). The control group in this study was
younger than the patient cohort (32.4 years vs. 56.1
years). To exclude a potential bias we investigated if age
and gender may influence the IL-22 serum concentration.
Age and gender were not associated with the systemic IL-
22 level in patients with liver cirrhosis (P > 0.2 for both).
Furthermore, the mean value of systemic IL-22 in healthy
controls obtained in this study was similar to the mean
systemic level of IL-22 in the literature reported for older
patients (3.3 ± 1.4 pg/ml, 51.6 ± 7.6 years) [27].
In order to determine a reference range, we used the
95% interval of lL-22 serum concentrations that were
observed in healthy donors. Based on that strategy, we
defined the upper limit of normal (ULN) serum IL-22
Figure 1 Study protocol.
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57 out of 120 (47.5%) patients with liver cirrhosis but
only 2 out of 40 (5.0%) healthy donors displayed ele-
vated IL-22 serum levels.
IL-22 serum levels increase in the course of liver disease
Next, we were interested whether IL-22 serum levels are
stably increased in the course of liver disease. Follow-up
sera were available in 29 patients with liver cirrhosis. Thir-
teen patients (44.8%) had elevated IL-22 serum levels at
baseline. After a mean follow-up of 138.2 ± 114.0 days, the
mean IL-22 serum level increased from 33.3 ± 49.2 pg/ml
to 61.3 ± 82.2 pg/ml (P = 0.0192, Figure 3). Only 3 of 13
patients (23.1%) with elevated IL-22 serum levels at base-
line showed a decline of IL-22 below the ULN at follow-
up while 9 of 16 patients (56.3%) with IL-22 serum levels
below the ULN at baseline showed an increase of IL-22
above ULN at follow-up.
IL-22 is detectable in livers from patients with liver
cirrhosis
A recent report demonstrates that IL-22 is produced
locally in livers of patients with chronic viral hepatitis [26].
In order to provide evidence that enhanced systemic IL-22
as observed herein likely derived from diseased liver tissue,
IL-22 expression was determined in liver biopsies by
immunohistochemical staining (available from only 10
patients, as liver biopsies aren o tr o u t i n e l yp e r f o r m e di n
patients with advanced liver cirrhosis). IL-22 positive cells
were observed in 7 of 10 liver biopsies from patients with
different etiologies of liver cirrhosis. In agreement with
Park et al. [26], IL-22 expression was detectable mainly in
non-parenchymal cells (Figure 4).
Table 1 Patient characteristics
Parameter
Patients, n 120
Male, n (%) 77 (64.2)
Age, mean ± SD (years) 56.1 ± 11.8
Weight, mean ± SD (kg) 77.8 ± 17.0
Hematology
Hb, mean ± SD (g/dl) 11.1 ± 2.8
Leukocytes, mean ± SD (10³) 6.8 ± 4.1
Thrombocytes, mean ± SD (/nl) 134.5 ± 167.3
Biochemistry
AST, mean ± SD (U/l) 74.9 ± 116.5
ALT, mean ± SD (U/l) 55.1 ± 150.5
GGT, mean ± SD (U/l) 186.6 ± 209.6
AP, mean ± SD (U/l) 148.2 ± 82.0
Total bilirubin, mean ± SD (mg/dl) 3.6 ± 5.6
INR, mean ± SD 2.3 ± 8.2
CRP, mean ± SD (ng/ml) 2.3 ± 3.1
Albumin, mean ± SD (g/l) 3.2 ± 0.6
Creatinine, mean ± SD (mg/dl) 1.3 ± 0.9
Prognosis score
MELD, mean (range) 16.3 (6.2 to 35.6)
Liver-related complications
Ascites, n (%) 68 (56.7)
Hepatorenal syndrome, n (%) 26 (21.7)
Spontaneous bacterial peritonitis, n (%) 13 (10.8)
Hepatic encephalopathy, n (%) 25 (20.8)
Variceal bleeding, n (%) 10 (8.3)
Etiology of liver disease
Chronic hepatitis B, n (%) 10 (8.3)
Chronic hepatitis C, n (%) 34 (28.3)
Alcohol, n (%) 54 (45.0)
PSC, n (%) 4 (3.3)
PBC, n (%) 2 (1.7)
Autoimmune, n (%) 3 (2.5)
Hemochromatosis n (%) 2 (1.7)
NASH, n (%) 2 (1.7)
Toxic, n (%) 2 (1.7)
Alpha1 antitrypsin deficiency 1 (0.8)
Cryptogenic 6 (5.0)
Normal reference ranges for male and female patients, respectively, were 13.7
to 17.5 and 11.2 to 15.7 g/dl for hemoglobin (Hb), 4.0 to 10.4 and 4.2 to 9.07/
nl for leukocytes, 163 to 337 and 182 to 369/nl for thrombocytes, 3.5 to 5.2
and 3.5 to 5.2 g/l for albumin. Upper limits of normal for male and female
patients, respectively, were 40 and 35 U/l for aspartate aminotransferase (AST),
50 and 35 U/l for alanine aminotransferase (ALT), 60 and 40 U/l for gamma
glutamyl transpeptidase (GGT), 130 and 105 U/l for alkaline phosphatase (AP),
1 and 1 mg/dl for total bilirubin, 0.5 and 0.5 ng/ml for C reactive protein
(CRP), 1.25 and 1.09 mg/dl for creatinine. MELD, Model of end stage liver
disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; SD,
standard deviation.
Figure 2 IL-22 serum concentrations are elevated in patients
with liver cirrhosis (n = 120) compared with healthy individuals
(n = 40). Dots indicate IL-22 serum levels in individual patients. The
straight horizontal line indicates the mean. The dotted horizontal line
indicates the upper limit of normal for IL-22 of 18 pg/ml. Error bars
indicate the standard deviation. Comparison between the two
groups was performed using the Mann Whitney U-test.
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We next investigated whether distinct etiologies of liver
diseases in the patient cohort under investigation affected
IL-22 serum levels. Notably, no significant differences
became apparent between levels of IL-22 in sera from
patients with liver cirrhosis due to chronic hepatitis B
(HBV), chronic hepatitis C (HCV) and alcoholic cirrhosis
(AC) (P > 0.2). For hereditary, cholestatic, autoimmune
liver diseases as well as toxic liver injury and non-
alcoholic steatohepatitis, the number of patients was too
low to draw a valid conclusion. Patients with chronic
HBV, chronic HCV and alcoholic cirrhosis had signifi-
cantly higher IL-22 serum levels than healthy controls
(P = 0.009, P < 0.001 and P < 0.001, respectively). These
data do not support an association between the etiology
of the underlying liver disease and elevated serum IL-22.
Elevated IL-22 serum levels are associated with reduced
survival of patients with liver cirrhosis
To investigate whether IL-22 serum levels are associated
with survival of patients with liver cirrhosis, we compared
survival of patients with liver cirrhosis and normal IL-22
levels (below the ULN of 18 pg/ml) with survival of
patients having elevated IL-22 serum levels (above the
ULN of 18 pg/ml). As illustrated in Figure 5, survival of
patients with elevated IL-22 serum levels was significantly
reduced compared to patients with normal IL-22 serum
levels (P = 0.003). The estimated mean survival time was
526.4 days for patients with normal systemic IL-22 and
321.3 days for patients with elevated IL-22 (Figure 5).
IL-22 serum levels are associated with complications of
liver cirrhosis
To investigate whether systemic IL-22 levels are asso-
ciated with complications of liver cirrhosis, we com-
pared liver cirrhosis-related complications between
patients with IL-22 serum levels above or below the
U L No f1 8p g / m l .E l e v a t e d IL-22 levels were more
frequent in patients with liver cirrhosis-related
Figure 3 C h a n g e so fI L - 2 2i nt h ec o u r s eo fl i v e rd i s e a s e .D o t s
indicate serum IL-22 levels in individual patients at baseline (BL) and
follow-up (FU), respectively. Corresponding IL-22 serum levels in
individual patients at BL and FU are connected. IL-22 serum levels
were analyzed in follow-up (FU) sera that were a minimum of 30
days apart from baseline (BL). The dotted horizontal line indicates the
upper limit of normal for IL-22 of 18 pg/ml. Comparison between BL
and FU was performed with the Wilcoxon matched pairs test.
Figure 4 Immunohistochemical detection of IL-22 in the liver. IL-22 positive cells were non-hepatocytic cells. IL-22 positive cells were
detected in cirrhotic livers with different etiologies. HCV, chronic hepatitis C (A); AC, alcoholic cirrhosis (B); arrows indicate typical IL-22 positive
cells which were different from hepatocytes. The inset shows a magnification of IL-22 positive cells.
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cirrhosis (60.0% vs. 17.1%, P < 0.001). Moreover,elevated
IL-22 serum levels were more frequent in patients with
ascites, hepatorenal syndrome (HRS) and spontaneous
bacterial peritonitis as compared to patients without
these complications (Figure 6).
IL-22 serum levels correlate with MELD score
The currently best-evaluated prognostic score for
patients with liver cirrhosis is the MELD score. In the
present study, there was a significant association
between high MELD score (≥20) and reduced survival
(P = 0.017, hazard ratio (HR) 0.364, confidence interval
(CI) (0.159 to 0.835)). As IL-22 serum levels were asso-
ciated with mortality of patients with liver cirrhosis, we
investigated the relation between the MELD score and
IL-22 serum levels. As shown in Figure 7, IL-22 serum
levels significantly correlated with the MELD score.
The MELD score includes the laboratory parameters
for creatinine, bilirubin and international normalized
ratio for prothrombin time (INR). Therefore, we also
investigated if the individual parameters of the MELD
score correlate with serum IL-22 levels in our patients.
As illustrated in Table 2, creatinine and INR but not
bilirubin correlated with IL-22 serum levels.
IL-22 serum levels correlate with surrogate parameters
for inflammation
To investigate whether IL-22 serum levels are associated
with determinants of liver synthetic capacity, inflammation
or damage, potential correlations of the cytokine with
serum albumin (surrogate marker of liver synthetic capa-
city), C-reactive protein (CRP, surrogate marker of ongoing
inflammation), and alanine aminotransferase (ALT) as well
Figure 5 Survival of patients with normal and elevated IL-22
serum levels. Kaplan-Meier curve for survival of patients with normal
(IL-22 ≤18 pg/ml, black line) and elevated IL-22 levels (IL-22 >18 pg/ml,
grey line). Survival was significantly higher in patients with normal vs.
elevated IL-22 serum levels according to the log rank test (P =0 . 0 0 3 ) .
The number of patients at risk is shown in the table below the plot.
Figure 6 Liver-related complications in patients with liver
cirrhosis according to IL-22 serum levels. Columns show the
percentage of patients with elevated serum IL-22 above 18 pg/ml
with (+) or without (-) liver related complications, ascites, hepatorenal
syndrome (HRS), spontaneous bacterial peritonitis (SBP) at time of IL-
22 quantification. Groups were compared by the Fisher test.
Figure 7 Correlation between MELD score and IL-22 serum
levels in patients with liver cirrhosis. The correlation coefficient
was calculated by the Spearman test.
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markers of liver damage, were analyzed (Table 2). A strong
positive correlation was found between serum IL-22 and
CRP levels (Table 2). Furthermore, weak but significant
inverse correlations between serum levels of IL-22 and
albumin, as well as ALT, were observed (Table 2).
Elevated IL-22 serum levels are predictive for reduced
survival independently from age, CRP, creatinine, MELD
score and presence of liver-related complications
In addition to MELD score and elevated IL-22, the factors
of high CRP (≥2.9 mg/dl) [28], elevated serum creatinine,
presence of liver-related complications, and age (P =
0.005, HR 0.314, CI (0.141 to 0.702); P =0 . 0 5 ,H R0 . 4 5 3 ,
CI (0.203 to 1.012); P = 0.028, HR 0.258, CI (0.077 to
0.862); P = 0.011, HR 0.955, CI (0.922 to 0.989)) were
associated with reduced overall survival in univariate ana-
lysis. Age-adjusted multivariate Cox proportional-hazards
analysis (including all significant variables in univariate
analysis) identified elevated systemic IL-22 levels as inde-
pendent predictors of reduced survival (P =0 . 0 0 7 ,H R
0.218, CI (0.072 to 0.662) for IL-22; P = 0.005, HR 0.93, CI
(0.89 to 0.98) for age). High CRP, elevated creatinine, pre-
sence of liver-related complications, and MELD score ≥20
were not predictive for survival in multivariate analysis
(P = 0.077, P > 0.2, P = 0.136 and P = 0.069, respectively).
We, furthermore, performed an AUC analysis to com-
pare MELD score and IL-22 levels for the ability to dis-
criminate patients who died during follow-up and those
who did not. In this analysis, serum IL-22 significantly
discriminated patients who died during the follow-up
period from those who survived (AUC 0.682, CI (0.560 to
0.805), P = 0.010). In contrast, the MELD score did not
identify patients who died during the follow-up period
(AUC 0.611, CI (0.470 to 0.752), P = 0.118).
Discussion
The role of IL-22 in disease progression of patients with
liver cirrhosis is currently uncertain. Lymphoid cells are
supposed to be the major source of IL-22 [3], though cells
of the macrophage/dendritic cell type have been likewise
reported to be capable of producing the cytokine [14,29].
In contrast, major liver targets of IL-22 are certainly hepa-
tocytes which express functional IL-22 receptors to a large
extent [22]. In the present study, we performed immuno-
histochemistry to confirm IL-22 expression in cirrhotic
livers. Indeed, IL-22 was detectable in non-parenchymal
cells in the hepatic lobe and in areas of necroinflamma-
tion. These observations are in agreement with previous
data from patients and murine models, suggesting that the
liver is an important source of serum IL-22 under condi-
tions of hepatic inflammation/injury [20,26].
The potential role of IL-22 in liver diseases has been
intensively studied in murine models for T cell-mediated
hepatitis [20], fulminant hepatic failure [30], alcoholic liver
injury [22] and regeneration after hepatectomy [31]. In
those models, IL-22 attenuated liver injury [20,22], pre-
vented hepatic failure [30] and improved hepatic steatosis
[22]. On the other hand, blockage of IL-22 bioactivity
increased liver injury [20] and was associated with
decreased hepatocyte proliferation following hepatectomy
[31]. On the whole, with the exception of experimental
hepatitis B virus infection [24], murine models largely sug-
gest a tissue protective function of IL-22 in hepatic
disorders.
The pathophysiological relevance and prognostic poten-
tial of serum IL-22 in patients with liver diseases of various
etiologies is less clear. The limited data available suggest
increased serum IL-22 in patients with acute HBV infec-
tion [24] and in patients with chronic hepatitis [23],
respectively. This latter study also links hepatocarcinogen-
esis to IL-22 function. IL-22 may be particularly important
for outcome of liver cirrhosis. To relate systemic IL-22 to
the prognosis of clinical liver cirrhosis, we performed a
prospective cohort study in which patients with advanced
liver cirrhosis were consecutively enrolled and longitudin-
ally followed. Our data show that, compared to healthy
donors, IL-22 serum levels were significantly elevated in
patients with liver cirrhosis. Furthermore, elevated IL-22
levels were associated with liver-related complications,
such as ascites, hepatorenal syndrome and spontaneous
bacterial peritonitis. These observations altogether indicate
that high IL-22 serum levels may reflect the severity of
liver disease.
IL-22 sera contents in healthy donors were, for the
most part, barely detectable and set the basis for calcu-
lation of a reference range. This reference range defined
levels below 18 pg/ml as being normal (ULN), which
agrees with previous reports on IL-22 in sera of healthy
donors obtained in the US and Europe [6,9,27,32].
Table 2 Correlation of the IL-22 serum concentration
with hematological and biochemical parameters
Parameter Spearman correlation, rP -value
Prognosis score
MELD 0.351 <0.001
Creatinine 0.271 0.004
Bilirubin 0.103 >0.2
INR 0.317 0.001
Synthesis
Albumin -0.222 0.028
Acute phase
CRP 0.432 <0.001
Liver enzymes
AST -0.093 >0.2
ALT -0.187 0.047
Tumor marker
AFP 0.018 >0.2
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cirrhosis showed elevated IL-22 serum concentrations.
Follow-up analyses of serum IL-22 levels in patients
with liver cirrhosis suggest that mean IL-22 levels
increase during the course of liver disease. The majority
of patients with elevated IL-22 baseline levels maintain
elevated levels during follow-up, while more than half of
patients with normal IL-22 serum levels at baseline
develop increased levels during follow-up. These results
indicate that IL-22 elevation is not a transient phenom-
enon in patients with liver cirrhosis. The mechanisms
mediating this IL-22 increase in the patients are not yet
clear. However, it can be assumed that increasing IL-22
levels are connected with increased cytokine production
as well as reduced hepatic or renal elimination.
Up-regulation of IL-22 might be associated with the
underlying etiology of liver cirrhosis. In the present study,
however, we observed no difference in the IL-22 levels in
sera from patients with prevalent etiologies of liver disease,
that is, HBV, HCV and alcoholic liver cirrhosis. In the
course of this study, hepatocellular carcinoma was diag-
nosed in two patients with detectable IL-22. This observa-
tion is in line with elevated systemic IL-22 in patients with
hepatocellular carcinoma [23].
Advanced liver cirrhosis is associated with poor prog-
nosis. Accordingly, prediction of hepatic deterioration is
key to efficient management of the clinical disease. In the
present study, approximately one quarter of patients died
after one year due to hepatic deterioration. The primary
goal of this study was to investigate whether serum IL-22
relates to survival of patients with liver cirrhosis. In fact,
serum IL-22 was significantly associated with survival.
However, patients with elevated serum IL-22 (>18 pg/ml)
levels showed reduced survival compared to those
patients with normal IL-22 levels indicating that pro-
cesses leading to deterioration of liver cirrhosis and its
sequelae come along with an increase of serum IL-22.
With respect to the hepatoprotective effects of IL-22 in
animal models, we assume that elevated IL-22 serum
levels in liver cirrhosis still ser v ep r o t e c t i v ef u n c t i o n s .
However, it cannot be excluded that IL-22 beyond a cer-
tain threshold may be pathogenic.
The best currently evaluated prognosis score for patients
with liver cirrhosis is the MELD score. Systemic IL-22
levels in patients with liver cirrhosis significantly corre-
lated with the MELD score, substantiating that IL-22 is
associated with deterioration of liver function and subse-
quent mortality of cirrhotic patients. The MELD score is a
short-term (three- to six-month) predictor of survival in
patients with end-stage liver disease, but is a weak predic-
tor of survival in patients with compensated liver cirrhosis
in the long term. In multivariate analysis, systemic IL-22
was (independently from age, presence of liver-related
complications, elevated creatinine, high CRP and high
MELD score) associated with long-term mortality. Taking
into account that IL-22 serum levels were stably increased
in the majority of patients in the course of liver cirrhosis,
the IL-22 serum level may be a valuable prognostic marker
for long-term survival of patients with advanced liver
cirrhosis.
The MELD score includes three blood surrogate para-
meters addressing different aspects of liver deterioration.
INR and bilirubin reflect liver synthetic capacity and
excretory function, while creatinine indicates renal
decompensation due to hepatic failure. IL-22 serum
levels correlated with two parameters of the MELD
score, that is, creatinine and INR. Furthermore, weak
inverse correlations were observed between systemic
IL-22 and serum albumin and ALT. The weak but sig-
nificant inverse correlation between the ALT level and
IL-22 serum level must be carefully interpreted, but may
indicate that IL-22 has a hepatoprotective function in
patients with advanced liver cirrhosis.
IL-22 also correlated with CRP, a well-established sur-
rogate marker of hepatic inflammation and prognosis of
liver cirrhosis [28]. CRP and creatinine were both asso-
ciated with serum IL-22, further suggesting that
enhanced systemic IL-22 is driven by hepatic inflamma-
tion along with renal deterioration. Whether IL-22
bioactivity likewise contributes to renal deterioration is
unknown
In contrast to the surrogate parameters currently used
for the assessment of the prognosis of liver cirrhosis, IL-22
likely plays an active role in liver inflammation, regenera-
tion and carcinogenesis [20,22,30,31]. Of particular inter-
est is the association among serum IL-22, CRP and
spontaneous bacterial peritonitis, indicating that IL-22
production is augmented by the infection. In fact, previous
studies showed up-regulation of the systemic IL-22 level
in patients with abdominal sepsis [9].
Conclusions
We demonstrate herein that elevated systemic IL-22
levels are predictive for reduced survival in patients with
liver cirrhosis independent of age, presence of liver-
related complications, CRP, creatinine and the MELD
score. Our data indicate that processes in the liver that
lead to deterioration of liver cirrhosis and its sequelae are
associated with an increase of IL-22. Overproduction of
IL-22 in liver cirrhosis may serve protective functions as
indicated by murine models of disease; however, IL-22
beyond a certain threshold may also be pathogenic.
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